Cargando…
Tocilizumab for severe COVID-19 pneumonia
| Autores principales: | , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier Ltd.
2020
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431121/ https://www.ncbi.nlm.nih.gov/pubmed/32838324 http://dx.doi.org/10.1016/S2665-9913(20)30282-4 |
| _version_ | 1783571532348391424 |
|---|---|
| author | Mourad, Jean-Jacques Azria, Philippe |
| author_facet | Mourad, Jean-Jacques Azria, Philippe |
| author_sort | Mourad, Jean-Jacques |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-7431121 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2020 |
| publisher | Elsevier Ltd. |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-74311212020-08-18 Tocilizumab for severe COVID-19 pneumonia Mourad, Jean-Jacques Azria, Philippe Lancet Rheumatol Correspondence Elsevier Ltd. 2020-11 2020-08-17 /pmc/articles/PMC7431121/ /pubmed/32838324 http://dx.doi.org/10.1016/S2665-9913(20)30282-4 Text en © 2020 Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active. |
| spellingShingle | Correspondence Mourad, Jean-Jacques Azria, Philippe Tocilizumab for severe COVID-19 pneumonia |
| title | Tocilizumab for severe COVID-19 pneumonia |
| title_full | Tocilizumab for severe COVID-19 pneumonia |
| title_fullStr | Tocilizumab for severe COVID-19 pneumonia |
| title_full_unstemmed | Tocilizumab for severe COVID-19 pneumonia |
| title_short | Tocilizumab for severe COVID-19 pneumonia |
| title_sort | tocilizumab for severe covid-19 pneumonia |
| topic | Correspondence |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7431121/ https://www.ncbi.nlm.nih.gov/pubmed/32838324 http://dx.doi.org/10.1016/S2665-9913(20)30282-4 |
| work_keys_str_mv | AT mouradjeanjacques tocilizumabforseverecovid19pneumonia AT azriaphilippe tocilizumabforseverecovid19pneumonia |